FORM Life Ventures

FORM Life Ventures is a San Francisco-based healthcare venture capital firm founded in 2022, co-founded by Markus Okumus (Founding Partner) and Professor Tony Wyss-Coray (Scientific Founder), a renowned Stanford University neuroscientist known for his research on aging and blood-based biomarkers. The firm funds and incubates companies leveraging science and technology to drive the shift from traditional sickcare toward proactive, preventive healthcare. FORM Life writes first checks of $500,000 to $2 million, investing at seed and Series A stages across the US, Israel, UK, and Germany. The portfolio of six companies spans healthtech, biotech, and drug discovery. Known investments include RxDiet, an AI-driven food-as-medicine platform targeting chronic illnesses such as diabetes and hypertension, which raised a $3 million seed round in July 2024 led by Giant Ventures with FORM Life participating. The portfolio also includes Indomo, a drug discovery therapeutics company that raised $42.2 million in total from investors including Foresite Capital and Atomic14 Ventures. Other portfolio companies include Vero Bioscience, People Science, Teal Rise, and additional health platform companies. FORM Life's investment themes span e-health, medical devices, diagnostics, longevity, agetech, proteomics, digital health, mental health, connected health, and biomarker-based approaches to medicine. Professor Wyss-Coray's scientific credentials and Stanford network provide the firm with privileged access to some of the most advanced biomedical research emerging from the university, while Okumus's operational focus on company building bridges the gap between academic discovery and commercial healthcare applications.